Dopamine receptor antagonists as potential therapeutic agents for ADPKD

Parama Paul, Sreekumar Ramachandran, Sheng Xia, Jay R. Unruh, Juliana Conkright-Fincham, Rong Li

Research output: Contribution to journalArticle

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is caused mostly by mutations in polycystin-1 or polycystin-2. Fluid flow leads to polycystin-dependent calcium influx and nuclear export of histone deacetylase 5 (HDAC5), which facilitates the maintenance of renal epithelial architecture by de-repression of MEF2C target genes. Here, we screened a small-molecule library to find drugs that promotes nuclear export of HDAC5. We found that dopamine receptor antagonists, domperidone and loxapine succinate, stimulate export of HDAC5, even in Pkd1-/-cells. Domperidone targets Drd3 receptor to modulate the phosphorylation of HDAC5. Domperidone treatment increases HDAC5 phosphorylation likely by reducing protein phosphatase 2A (PP2A) activity, thus shifting the equilibrium towards HDAC5-P and export from the nucleus. Treating Pkd1-/-mice with domperidone showed significantly reduced cystic growth and cell proliferation. Further, treated mice displayed a reduction in glomerular cyst and increased body weight and activity. These results suggest that HDAC5 nucleocytoplasmic shuttling may be modulated to impede disease progression in ADPKD and uncovers an unexpected role for a class of dopamine receptors in renal epithelial morphogenesis.

Original languageEnglish (US)
Pages (from-to)e0216220
JournalPloS one
Volume14
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Autosomal Dominant Polycystic Kidney
histone deacetylase
Histone Deacetylases
Dopamine Antagonists
antagonists
Domperidone
therapeutics
Phosphorylation
Cell Nucleus Active Transport
Therapeutics
phosphorylation
Loxapine
TRPP Cation Channels
kidneys
Small Molecule Libraries
Kidney
Protein Phosphatase 2
phosphoprotein phosphatase
mice
Dopamine Receptors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Paul, P., Ramachandran, S., Xia, S., Unruh, J. R., Conkright-Fincham, J., & Li, R. (2019). Dopamine receptor antagonists as potential therapeutic agents for ADPKD. PloS one, 14(5), e0216220. https://doi.org/10.1371/journal.pone.0216220

Dopamine receptor antagonists as potential therapeutic agents for ADPKD. / Paul, Parama; Ramachandran, Sreekumar; Xia, Sheng; Unruh, Jay R.; Conkright-Fincham, Juliana; Li, Rong.

In: PloS one, Vol. 14, No. 5, 01.01.2019, p. e0216220.

Research output: Contribution to journalArticle

Paul, P, Ramachandran, S, Xia, S, Unruh, JR, Conkright-Fincham, J & Li, R 2019, 'Dopamine receptor antagonists as potential therapeutic agents for ADPKD', PloS one, vol. 14, no. 5, pp. e0216220. https://doi.org/10.1371/journal.pone.0216220
Paul P, Ramachandran S, Xia S, Unruh JR, Conkright-Fincham J, Li R. Dopamine receptor antagonists as potential therapeutic agents for ADPKD. PloS one. 2019 Jan 1;14(5):e0216220. https://doi.org/10.1371/journal.pone.0216220
Paul, Parama ; Ramachandran, Sreekumar ; Xia, Sheng ; Unruh, Jay R. ; Conkright-Fincham, Juliana ; Li, Rong. / Dopamine receptor antagonists as potential therapeutic agents for ADPKD. In: PloS one. 2019 ; Vol. 14, No. 5. pp. e0216220.
@article{6570f4f53c9043b2a9d33585dcc82b81,
title = "Dopamine receptor antagonists as potential therapeutic agents for ADPKD",
abstract = "Autosomal dominant polycystic kidney disease (ADPKD) is caused mostly by mutations in polycystin-1 or polycystin-2. Fluid flow leads to polycystin-dependent calcium influx and nuclear export of histone deacetylase 5 (HDAC5), which facilitates the maintenance of renal epithelial architecture by de-repression of MEF2C target genes. Here, we screened a small-molecule library to find drugs that promotes nuclear export of HDAC5. We found that dopamine receptor antagonists, domperidone and loxapine succinate, stimulate export of HDAC5, even in Pkd1-/-cells. Domperidone targets Drd3 receptor to modulate the phosphorylation of HDAC5. Domperidone treatment increases HDAC5 phosphorylation likely by reducing protein phosphatase 2A (PP2A) activity, thus shifting the equilibrium towards HDAC5-P and export from the nucleus. Treating Pkd1-/-mice with domperidone showed significantly reduced cystic growth and cell proliferation. Further, treated mice displayed a reduction in glomerular cyst and increased body weight and activity. These results suggest that HDAC5 nucleocytoplasmic shuttling may be modulated to impede disease progression in ADPKD and uncovers an unexpected role for a class of dopamine receptors in renal epithelial morphogenesis.",
author = "Parama Paul and Sreekumar Ramachandran and Sheng Xia and Unruh, {Jay R.} and Juliana Conkright-Fincham and Rong Li",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0216220",
language = "English (US)",
volume = "14",
pages = "e0216220",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Dopamine receptor antagonists as potential therapeutic agents for ADPKD

AU - Paul, Parama

AU - Ramachandran, Sreekumar

AU - Xia, Sheng

AU - Unruh, Jay R.

AU - Conkright-Fincham, Juliana

AU - Li, Rong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Autosomal dominant polycystic kidney disease (ADPKD) is caused mostly by mutations in polycystin-1 or polycystin-2. Fluid flow leads to polycystin-dependent calcium influx and nuclear export of histone deacetylase 5 (HDAC5), which facilitates the maintenance of renal epithelial architecture by de-repression of MEF2C target genes. Here, we screened a small-molecule library to find drugs that promotes nuclear export of HDAC5. We found that dopamine receptor antagonists, domperidone and loxapine succinate, stimulate export of HDAC5, even in Pkd1-/-cells. Domperidone targets Drd3 receptor to modulate the phosphorylation of HDAC5. Domperidone treatment increases HDAC5 phosphorylation likely by reducing protein phosphatase 2A (PP2A) activity, thus shifting the equilibrium towards HDAC5-P and export from the nucleus. Treating Pkd1-/-mice with domperidone showed significantly reduced cystic growth and cell proliferation. Further, treated mice displayed a reduction in glomerular cyst and increased body weight and activity. These results suggest that HDAC5 nucleocytoplasmic shuttling may be modulated to impede disease progression in ADPKD and uncovers an unexpected role for a class of dopamine receptors in renal epithelial morphogenesis.

AB - Autosomal dominant polycystic kidney disease (ADPKD) is caused mostly by mutations in polycystin-1 or polycystin-2. Fluid flow leads to polycystin-dependent calcium influx and nuclear export of histone deacetylase 5 (HDAC5), which facilitates the maintenance of renal epithelial architecture by de-repression of MEF2C target genes. Here, we screened a small-molecule library to find drugs that promotes nuclear export of HDAC5. We found that dopamine receptor antagonists, domperidone and loxapine succinate, stimulate export of HDAC5, even in Pkd1-/-cells. Domperidone targets Drd3 receptor to modulate the phosphorylation of HDAC5. Domperidone treatment increases HDAC5 phosphorylation likely by reducing protein phosphatase 2A (PP2A) activity, thus shifting the equilibrium towards HDAC5-P and export from the nucleus. Treating Pkd1-/-mice with domperidone showed significantly reduced cystic growth and cell proliferation. Further, treated mice displayed a reduction in glomerular cyst and increased body weight and activity. These results suggest that HDAC5 nucleocytoplasmic shuttling may be modulated to impede disease progression in ADPKD and uncovers an unexpected role for a class of dopamine receptors in renal epithelial morphogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85065639553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065639553&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0216220

DO - 10.1371/journal.pone.0216220

M3 - Article

VL - 14

SP - e0216220

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

ER -